Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Cacciarelli TV et al. | An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1999 | Transplantation | pmid:10507484 |
Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
Lykavieris P et al. | Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. | 2003 | Transplantation | pmid:12544888 |
Moffatt SD et al. | Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. | 1999 | Transplantation | pmid:10342309 |
Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
Jindal RM et al. | Effect of deoxyspergualin on the endocrine function of the rat pancreas. | 1993 | Transplantation | pmid:7504347 |
Millis JM et al. | Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. | 1996 | Transplantation | pmid:8629298 |
Maes BD et al. | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 | Transplantation | pmid:11726827 |
Toso C et al. | Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. | 2003 | Transplantation | pmid:14557767 |
King-Biggs MB et al. | Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. | 2003 | Transplantation | pmid:12792493 |
Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
Hricik DE et al. | Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2007 | Transplantation | pmid:17297401 |
Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
Jain A et al. | Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. | 2000 | Transplantation | pmid:10972220 |
Sharif A et al. | Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. | 2010 | Transplantation | pmid:20145524 |
Jordan ML et al. | Long-term results of pancreas transplantation under tacrolius immunosuppression. | 1999 | Transplantation | pmid:10075592 |
Khanna AK | Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. | 2000 | Transplantation | pmid:10972232 |
Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
Kaplan B et al. | Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. | 1996 | Transplantation | pmid:8900321 |
Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
Merkle M et al. | The effect of sevelamer on tacrolimus target levels. | 2005 | Transplantation | pmid:16177649 |
Kadry Z et al. | Kaposi's sarcoma in liver transplant recipients on FK506. | 1998 | Transplantation | pmid:9583882 |
Batten P et al. | Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro. | 1999 | Transplantation | pmid:10589954 |
Demmers MW et al. | Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. | 2014 | Transplantation | pmid:24157471 |
Thorp M et al. | The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. | 2000 | Transplantation | pmid:10762229 |
Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
Fealy MJ et al. | Association of down-regulation of cytokine activity with rat hind limb allograft survival. | 1995 | Transplantation | pmid:7539555 |
Yang H et al. | Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. | 2002 | Transplantation | pmid:11907415 |
St A Nunes FA and Lucey MR | Searching for a balance when applying immunosuppression after liver transplantation. | 2001 | Transplantation | pmid:11258425 |
Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
Klein A et al. | Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. | 2009 | Transplantation | pmid:19300186 |
Mikhalski D et al. | Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. | 2008 | Transplantation | pmid:18401260 |
Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
Gibson SW et al. | Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. | 2000 | Transplantation | pmid:10852592 |
Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
Warty V et al. | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. | 1988 | Transplantation | pmid:2458643 |
Lerut J et al. | Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. | 2005 | Transplantation | pmid:16314784 |
Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |
Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |
Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |